"USA Mitchell Cancer Institute is providing exceptional care for cancer patients through innovative treatment and clinical research."

During the past decade, University of South Alabama Mitchell Cancer Institute conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 55 clinical trials were completed, i.e. on average, 119.6% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 32 clinical trials were completed. i.e. 160% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of South Alabama Mitchell Cancer Institute" #1 sponsor was "National Cancer Institute (NCI)" with 31 trials, followed by "Alliance for Clinical Trials in Oncology" with 8 trials sponsored, "SWOG Cancer Research Network" with 8 trials sponsored, "Novartis Pharmaceuticals" with 6 trials sponsored and "Gynecologic Oncology Group" with 6 trials sponsored. Other sponsors include 46 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of South Alabama Mitchell Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 36 trials as a collaborator, "NRG Oncology" with 12 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator, "NCIC Clinical Trials Group" with 4 trials as a collaborator and "SWOG Cancer Research Network" with 4 trials as a collaborator. Other collaborators include 59 different institutions and companies that were collaborators in the rest 62 trials.

According to Clinical.Site data, the most researched conditions in "University of South Alabama Mitchell Cancer Institute" are "Breast Cancer" (11 trials), "Recurrent Ovarian Carcinoma" (6 trials), "Stage II Breast Cancer" (6 trials), "Cervical Cancer" (5 trials) and "Fallopian Tube Transitional Cell Carcinoma" (5 trials). Many other conditions were trialed in "University of South Alabama Mitchell Cancer Institute" in a lesser frequency.

Most popular intervention types in "University of South Alabama Mitchell Cancer Institute" are "Drug" (83 trials), "Other" (40 trials), "Biological" (29 trials), "Procedure" (18 trials) and "Radiation" (18 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (24 trials), "Paclitaxel" (19 trials), "Quality-of-Life Assessment" (18 trials), "Placebo" (12 trials) and "Carboplatin" (11 trials). Other intervention names were less common.

The vast majority of trials in "University of South Alabama Mitchell Cancer Institute" are 68 trials for "All" genders, 36 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "University of South Alabama Mitchell Cancer Institute". undefined are not yet recruiting, 9 are recruiting, 47 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 42 completed trials in University of South Alabama Mitchell Cancer Institute, 2 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in University of South Alabama Mitchell Cancer Institute, 2 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".